Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

By Douglas G. Altman, Lisa M. McShane, Willi Sauerbrei, S. Taube. PLoS Medicine, 2012

879 citations recorded by the source corpus.

The REMARK “elaboration and explanation” guideline, by Doug Altman and colleagues, provides a detailed reference for authors on important issues to consider when designing, conducting, and analyzing tumor marker prognostic studies.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/7417e9ecae4f296ac25071e9a0b548d5729b0055

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Gary S. Collins
2. Karel G. M. Moons
3. Johannes B Reitsma

In Pulmonary and Respiratory Medicine

1. Nikos Paragios
2. Gary S. Collins
3. Karel G. M. Moons
4. Johannes B Reitsma

In Radiology, Nuclear Medicine and Imaging

1. Gary S. Collins
2. Johannes B Reitsma
3. Nikos Paragios
4. Karel G. M. Moons
5. Ronald M. Summers
6. Martin Burger
7. Stanley J. Osher
8. Shijun Wang

Citations in the corpus

• Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series (2018, methodology): “REMARK [17] reporting criteria were followed, with full description of statistical methods in the supplementary methods, available at Annals of Oncology online.”
• Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement (2015, neutral): “in a similar style to those for other reporting guidelines [47-49].”
• Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology (2017, methodology): “In the same way as the REporting recommendations for tumour MARKer prognostic studies (REMARK) [106] or the Minimum information about a microarray experiment (MIAME) [107] guidelines, recommendations specific to radiomics are necessary.”
• Radiomics: the bridge between medical imaging and personalized medicine (2017, neutral): “Rigorous reporting guidelines are necessary for radi-omics to mature 42–44 .”
• Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015, neutral): “in a similar style to those for other reporting guidelines [47-49].”
• An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018, methodology): “Similar to Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting randomized clinical trials (Schulz et al., 2010), REMARK seeks to improve the transparency and reproducibility of prognostic marker studies.”
• Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement (2015, positive): “THE TRIPOD EXPLANATION AND ELABORATION DOCUMENT In addition to the TRIPOD Statement, we produced a supporting explanation and elaboration document (Moons et al, 2015) in a similar style to those for other reporting guidelines (Vandenbroucke et al, 2007; Janssens et al, 2011a; Altman et al, 2012).”